Abdulrahman, 446 patient HCQ late treatment PSM study: 17% lower mortality [p=1] and 75% higher combined mortality/intubation [p=0.24] https://c19p.org/abdulrahman
copied to clipboard
The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort
et al., medRxiv, doi:10.1101/2020.11.25.20234914 (Preprint)
Retrospective medical record analysis of acute care patients in Bahrain not showing a significant effect of HCQ.Confounding by indication is likely. Matching appears not to have matched for baseline severity - 17.5% of HCQ patients required oxygen while only 12.6% of control patients did.
|
risk of death, 16.7% lower, RR 0.83, p = 1.00, treatment 5 of 223 (2.2%), control 6 of 223 (2.7%), NNT 223, PSM.
|
|
risk of death/intubation, 75.0% higher, RR 1.75, p = 0.24, treatment 12 of 223 (5.4%), control 7 of 223 (3.1%), adjusted per study, PSM.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Abdulrahman et al., 11/30/2020, retrospective, propensity score matching, Bahrain, Middle East, preprint, 9 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.